FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Novartis | Intercell
Syndicate content

Intercell and Novartis collaborate on Pseudomonas vax

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Intercell and Novartis are continuing to test an investigational vaccine for Pseudomonas aeruginosa. The disease can cause nosocomial infections that lead to pneumonia and other infections, usually during hospital stays, particularly in patients on ventilators. The 400-patient efficacy trial should start in the first half of 2012. Intercell release

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Novartis   Intercell  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.